Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human PRMT5 Antikörper:
anti-Mouse (Murine) PRMT5 Antikörper:
anti-Rat (Rattus) PRMT5 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal PRMT5 Primary Antibody für IHC (p), IHC - ABIN258206
Pak, Lee, Roh: High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma. in Pathology international 2015
Human Polyclonal PRMT5 Primary Antibody für WB - ABIN4347350
Guo, Zheng, Xu, Dai, Zhou, Pascua, Chen, Shen: Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. in Nature chemical biology 2010
he phosphorylation of the MP inhibitory MYPT1(T850) and the regulatory PRMT5(T80) residues as well as the symmetric dimethylation of H2A/4 were elevated in human hepatocellular carcinoma and in other types of cancers.
The polymerase-associated factor complex regulates Prmt5 to facilitate leukemic progression and is a potential therapeutic target for acute myeloid leukemias.
our results indicated that PRMT5 overexpression in hepatocellular carcinoma (HCC (zeige FAM126A Antikörper))and colon cancer cells contributed to their acquisition of aggressive characteristics, such as invasiveness, thus presenting a promising therapeutic target for the treatment of these diseases
PRMT5 as a key in vitro and in vivo regulator of breast cancer stem cells proliferation. PRMT5 epigenetically regulates FOXP1 (zeige FOXP1 Antikörper).
Protein arginine methyltransferase 5 (PRMT5) was identified to be responsible for Eno-1 methylation. Overexpression of PRMT5 and caveolin-1 (zeige CAV1 Antikörper) enhanced levels of membrane-bound extracellular Eno-1 and, conversely, pharmacological inhibition of PRMT5 attenuated Eno-1 cell-surface localization.
A 3.7 A structure of PRMT5, solved in complex with regulatory binding subunit MEP50 (zeige WDR77 Antikörper) (methylosome associated protein 50, WDR77 (zeige WDR77 Antikörper), p44 (zeige GTF2H2 Antikörper)), by single particle (SP) cryo-Electron Microscopy (cryo-EM) using micrographs of particles that are visibly crowded and aggregated. The catalytic PRMT5 subunits form a core tetramer and the MEP50 (zeige WDR77 Antikörper) subunits are arranged peripherally in complex with the PRMT5 N-terminal domain.
These kinetic studies suggest a biochemical explanation for the interplay between PRMT5- and PRMT7 (zeige PRMT7 Antikörper)-mediated methylation of the same substrate at different residues and also suggest a general model for regulation of PRMTs.
Data indicate the significant potential of PRMT5 as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC (zeige CALR Antikörper)).
PRMT5 inhibited the interaction between CDK4 (zeige CDK4 Antikörper) and CDKN2A and then activated the CDK4 (zeige CDK4 Antikörper)-RB-E2F (zeige E2F1 Antikörper) pathway in hepatocellular carcinoma cells under glucose induction.
Data suggest that the protein arginine methyltransferase 5 (PRMT5)-E2F1 transcription factor (E2F-1 (zeige E2F1 Antikörper)) pathway may act as a common target for exogenous lectins including Anguilla japonica lectin 1 (AJL1), and the cellular response to exogenous AJL1 may suggest a novel agent for cancer gene therapy.
observed the progressive decrease in PRMT5 during oligodendrocyte differentiation
the present study increases our understanding of PRMT1 (zeige PRMT1 Antikörper), -4, and -5 biology during the plasticity of skeletal muscle development. Our results provide evidence for a role of PRMT1 (zeige PRMT1 Antikörper), via a mitochondrially mediated mechanism, in driving the muscle differentiation program.
the nuclear localized CA-VI (zeige CA6 Antikörper) B selectively promotes IL-12 (zeige IL12A Antikörper) expression by interaction with protein arginine N-methyltransferase 5 (PRMT5), which reduces symmetric dimethylation of histone H3 (zeige HIST3H3 Antikörper) arginine 8 modification (H3R8me2s) at Il12 (zeige IL12A Antikörper) promoters to facilitate chromatin accessibility, selectively enhancing c-Rel (zeige NFkBP65 Antikörper) binding to the Il12b (zeige IL12B Antikörper) promoter.
this study demonstrates for the first time that oncogenic stress orchestrates a p53 (zeige TP53 Antikörper)-dependent response that is controlled by PRMT5-mediated arginine methylation and identifies the Fanconi anemia (zeige PALB2 Antikörper) pathway as an integral part of this versatile cellular mechanism
PRMT5 is an osteoclastogenesis activator and PRMT5 inhibition suppresses osteoclast differentiation via downregulation of CXCL10 (zeige CXCL10 Antikörper) and RSAD2 (zeige RSAD2 Antikörper).
PRMT1 (zeige PRMT1 Antikörper) inhibition prevents gastric cancer progression by downregulating eIF4E (zeige EIF4E Antikörper) and targeting type II PRMT5.
PRMT5 regulates internal ribosome entry site-dependent translation via methylation of hnRNP A1 (zeige HNRNPA1 Antikörper).
PRMT5 maintains progenitor cells through its regulation of Bmp4 (zeige BMP4 Antikörper); adult and embryonic stem cells also require PRMT5 for maintaining pluripotency, suggesting that similar mechanisms might regulate lineage-restricted progenitor cells during organogenesis.
Menin and PRMT5 suppress GLP1R (zeige GLP1R Antikörper) transcript levels and PKA-mediated phosphorylation of FOXO1 (zeige FOXO1 Antikörper) and CREB (zeige CREB1 Antikörper).
findings show that PRMT5 is an important modulator of CD4 (zeige CD4 Antikörper)(+) T cell expansion; PRMT5 was transiently upregulated during maximal proliferation of mouse and human memory Th cells; data implicate PRMT5 in the regulation of adaptive memory Th cell responses
a combinatorial role of PRMT4/CARM1 (zeige CARM1 Antikörper) and PRMT5 for proper myogenesis in zebrafish
Data indicate that MEP50 (zeige WDR77 Antikörper) WD repeat protein (zeige DCAF7 Antikörper) is essential for methylation of histones H4 and H2A (zeige H2AFX Antikörper) by PRMT5 arginine methyltransferase.
data support a mechanism in which MEP50 (zeige WDR77 Antikörper) binds substrate and stimulates PRMT5 activity modulated by substrate post-translational modifications
Protein arginine methyltransferase Prmt5-Mep50 (zeige WDR77 Antikörper) methylates histones H2A (zeige H2AFX Antikörper) and H4 and the histone chaperone nucleoplasmin (zeige NPM1 Antikörper) in Xenopus laevis eggs
The results suggested that medaka Mep50 (zeige WDR77 Antikörper) could be a partner of Prmt5 and might play major roles in a variety of tissues in medaka.
It show the morphological and functional phenotypes of single or double null alleles of prmt-5 in Caenorhabditis elegans. The prmt-1 (zeige PRMT1 Antikörper);prmt-5 double mutants are viable, and exhibit short body length and small brood size compared to N2 and each of the single mutants.
The PRMT-5 catalyzes the symmetric dimethylation of substrates containing monomethylarginine residues in vivo.
Analysis of prmt-5-deficient worms indicated that methylation promoted the dopamine-mediated modulation of chemosensory and locomotory behaviors through the DOP (zeige COPB2 Antikörper)-3 receptor.
data confirm that MEP50 (zeige WDR77 Antikörper) plays a key role in substrate recognition and activates PRMT5 activity by increasing its affinity for protein substrates.
the substrate specificity, processivity, and kinetic mechanism of bacterially expressed Caenorhabditis elegans PRMT5 (cPRMT5).
analysis of structural insights into protein arginine symmetric dimethylation by PRMT5
PRMT-5 represses CEP-1 transcriptional activity through CBP-1, which represents a novel regulatory mechanism of p53 (zeige TP53 Antikörper)-dependent apoptosis.
Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3)\; such methylation being required for the assembly and biogenesis of snRNP core particles. Methylates SUPT5H. Mono- and dimethylates arginine residues of myelin basic protein (MBP) in vitro. Plays a role in the assembly of snRNP core particles. May play a role in cytokine-activated transduction pathways. Negatively regulates cyclin E1 promoter activity and cellular proliferation. May regulate the SUPT5H transcriptional elongation properties. May be part of a pathway that is connected to a chloride current, possibly through cytoskeletal rearrangement. Methylates histone H2A and H4 'Arg-3' during germ cell development. Methylates histone H3 'Arg-8', which may repress transcription. Methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage. Methylates RPS10. Attenuates EGF signaling through the MAPK1/MAPK3 pathway acting at 2 levels. First, monomethylates EGFR\; this enhances EGFR 'Tyr-1197' phosphorylation and PTPN6 recruitment, eventually leading to reduced SOS1 phosphorylation. Second, methylates RAF1 and probably BRAF, hence destabilizing these 2 signaling proteins and reducing their catalytic activity (By similarity). Required for induction of E-selectin and VCAM-1, on the endothelial cells surface at sites of inflammation (By similarity). Methylates HOXA9 (By similarity).
72 kDa ICln-binding protein
, HMT1 hnRNP methyltransferase-like 5
, SKB1 homolog
, histone-arginine N-methyltransferase PRMT5
, jak-binding protein 1
, protein arginine N-methyltransferase 5
, shk1 kinase-binding protein 1 homolog
, protein arginine methyltransferase 5
, Jak-binding protein 1
, putative arginine N-methyltransferase, type II
, protein arginine methyltransferase
, protein arginine N-methyltransferase 5-like